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Summary Acid soluble proteins from 23 samples of normal human gastrointestinal mucosa dervied from four
normal adult organ donors were extracted and subjected to specific radiommunoassays for transforming
growth factor a (TGFa) and urogastrone epidermal growth factor (URO-EGF). All tissues were found to
contain immunoreactive TGFa and levels ranged from 57 to 4,776 pg-' wet weight of tissue. Although levels
varied between tissue donors, the distribution of TGFa throughout the gastrointestinal tract appeared similar
in all cases. URO-EGF levels were much lower (0-216pgg-' wet weight). TGFa levels in extracts of
gastrointestinal mucosa from a 7-year-old female donor were higher and the observed distribution was
markedly different from adult levels. URO-EGF was not detected in mucosal or submucosal tissue extracts
from this patient. Further studies in juveniles are indicated.
Transforming growth factor a (TGFa) and urogastrone
epidermal growth factor (URO-EGF) are mitogenic polypep-
tides of similar size and structure (Marquardt et al., 1983)
which both interact with the same receptor. They appear to
be functionally equivalent and equipotent in their ability to
stimulate mitotic activity (Anzano et al., 1982) and cell
differentiation (Smith et al., 1985), but marked differences in
their actions on regional blood flow have been documented
(Gan et al., 1987). Moreover, the genes for TGFa and URO-
EGF are different in both structure and chromosomal loca-
tion (Sporn & Roberts, 1986). The physiological role of these
peptides remains unclear, although it has been proposed by
many that URO-EGF plays a role in wound healing, tissue
maintenance and post-natal hepatic growth and maturation
(Opleta et al., 1987). Furthermore, evidence for a
physiological function of URO-EGF is suggested by
decreased milk production and increased offspring mortality
produced by pregestational sialoadenectomy in mice
(Okamoto & Oka, 1984). TGFa is produced by a number of
embryonic and transformed cells (Goustin et al., 1986) and
increased levels of both peptides have been detected in the
urine of cancer patients (Kim et al., 1985).
Immunocytochemical studies on human tissues have shown
that URO-EGF is localised in the submandibular glands,
Brunner's glands (Elder et al., 1978) and in specialised cells
of the stomach (Elder et al., 1986). Immunoreactive URO-
EGF has also been detected in various body fluids including
urine (Gregory, 1975), saliva, gastric juice (Gregory et al.,
1979), breast milk (Hirata & Orth, 1979) and blood, where it
is thought to be contained largely in platelets (Oka & Orth,
1983). The URO-EGF receptor is widespread and has been
well characterised biochemically (Ullrich et al., 1984) and is
known to be a ligand regulated receptor kinase.
It has been suggested that TGFa is functional during
embryonic development and is abnormally expressed by
tumour cells resulting in autocrine secretion and tumour
growth promotion (Sporn & Roberts, 1985). Although
sporadic reports have appeared in the literature of TGFa
concentrations in the plasma and urine (Yeh et al., 1987;
Kim et al., 1985) of normal and cancer patients, to our
knowledge normal adult human body tissues have not been
examined for the presence of this peptide. We have,
therefore, examined normal gastrointestinal tissue extracts for
the presence and amounts of TGFa and URO-EGF using
specific radioimmunoassays for these peptides.
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Materials and methods
Tissues
With the permission of HM Coroner and the Coroner's
pathologist for North Staffordshire, 30 samples of gast-
rointestinal tissues of lengths 15-30cm were obtained from
five normal organ donors (three male and one female adults
(age range 19-44 years) and one 7-year-old female) as
quickly as possible following organ donation and in all cases
within 90 min of cessation of cardiac action. Samples of
stomach, duodenum, jejunum, ileum, ascending colon, trans-
verse colon, descending and sigmoid colon were frozen in
liquid nitrogen before transportation to the laboratory.
Extraction ofacidsolubleproteins
Tissues were partially thawed and the dissection of mucosa
from submucosa was carried out on ice. Acid-ethanol extrac-
tion of tissues was carried out using a modification of the
method described by Roberts et al. (1980) for the isolation of
transforming growth factors.
Tissues were homogenised using a Silverson Laboratory
Mixer (Silverson Machines Ltd, Chesham, Bucks., UK) in
4 ml g-' of a solution comprising 375 ml of 95% (v/v)
ethanol, 7.5 ml ofconcentrated HCI, 33 mg ofphenylmethyl-
sulphonyl fluoride and 1.9 mg of pepstatin. The volume was
adjusted to 6 ml g-' with distilled water and extracted over-
night at 4°C. Mixtures were centrifuged and pellets re-
extracted overnight with 4 ml g-' (original weight) of a solu-
tion containing 375 ml of 95% ethanol, 7.5 ml concentrated
HCI and 105 ml distilled water. Supernatants were combined
and adjusted to pH 5.2 followed by the addition of 1 ml of
2 M ammonium phosphate buffer (pH 5.2) per 85 ml extract.
Two volumes ofcold anhydrous ethanol and four volumes of
cold anhydrous ether were added, and the mixture allowed to
stand for 48 h at room temperature. The resulting precipitate
was collected by filtration through Whatman no. 1 paper and
redissolved in 1M acetic acid (3.5 ml-' of original tissue
weight). Extracts were dialysed extensively against 0.1 M
acetic acid (Spectrapor tubing, molecular weight cut-off
3,500, Spectrum Medical Industries, Los Angeles, CA).
Radioimmunoassayfor hURO-EGFandhTGF
Lyophilised extracts were redissolved in 5-10 ml 0.04 M
phosphate buffer containing 0.15 M NaCl, 0.1 M EDTA and
0.1% sodium azide at pH 4.5 to optimise peptide dissolution.
The assays were not affected by sample pH in the range
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4.2-7.2. Extracts were filtered through 0.2 m Acrodisc 13
filters (Gelman Science Ltd, Northampton, UK).
Peptides and specific polyclonal antibodies to hURO-EGF
and hTGFax were received as gifts from Dr H. Gregory (ICI
plc). The antibody to hTGFa was raised in sheep and the
EGF antibody was raised in rabbits.
hURO-EGF (6 kDa) and hTGF (5.6 kDa) were
radioiodinated using the lodogen method. Resultant specific
activities were 150-200 Ci .tg-'. Standards, controls and
samples were diluted in phosphate buffer pH 4.5. Antibodies
were diluted in as,say buffer comprising 0.04M phosphate
buffer (pH 7.2) containing 0.15 M NaCl, 0.01 M EDTA,
0.1% sodium azide and 0.5% BSA, to which 4gil ml-' nor-
mal rabbit or sheep serum was added. The hURO-EGF
antibody was used at a dilution of 1 in 20,000 and the
hTGFa antibody at 1 in 25,000. Samples, standards and
controls (250gil) were mixed with 250gil antibody followed
by 250 gil `25I-hTGF (containing 25 pg). Following incubation
at 4°C for 72 h, 250;gl of precipitating antibody (donkey
anti-rabbit or donkey anti-sheep, IDS, Washington, Tyne
and Wear, UK) was added at appropriate dilution and
incubation continued for a further 24 h at 4°C. Separation of
the resultant precipitate was by centrifugation at 2500 r.p.m.
at 4°C for 30 min followed by aspiration of supernatant.
The antibody to hTGFa shows non cross-reaction with
hURO-EGF at a 2,000-fold greater concentration and the
TGFa RIA is sensitive within the range 25 pg to 12.5 ng. The
hURO-EGF antibody shows no cross reaction with hTGFa
also at a 2,000-fold greater concentration and the hURO-
EGF RIA is sensitive within the range 10pg to 2.5 ng.
Reverse phase chromatography
Normal gastric mucosal extract (500 gil containing 5 mg of
acid soluble protein) in phosphate buffer pH 4.5 was applied
to a Pep RPC 5/5 HR reverse phase column (Pharmacia Ltd,
Milton Keynes, Bucks., UK) previously equilibrated with
0.1% trifluoacetic acid (TFA). The column was then eluted
at a flow rate of 1 ml min-' at room temperature with a
0-40% linear gradient of acetonitrile containing 0.1% TFA.
One millilitre fractions were collected, lyophilised and redis-
solved in assay buffer before radioimmunoassay for hURO-
EGF and hTGFx.
Results
Immunoreactive hTGFa was detected in all of the tissue
extracts examined (Figure 1); individual results on each sam-
ple are availabie from the authors on request. Although
tissues were largely derived from only three adults, and
absolute levels varied between individuals, the distribution of
hTGFa throughout the gastrointestinal tract mucosa
appeared similar. hTGFa levels declined significantly from
the gastric mucosa (mean 2,232 pg hTGFx per gram wet
weight of tissue) to the duodenal mucosa (396pgg-') and
gradually rose again through the ileum (1,290 pgg') and
ascending colon (2,173 pg g-') to decrease again through to
the sigmoid colon mucosa (530pgg-').
EGF immunoreactivity was detected in all but two of the
tissue extracts, but levels (0-216pg hURO-EGF per gram
wet weight of mucosa) were much lower than hTGFa levels
in the same tissue extracts. There was no apparent pattern in
the distribution of hURO-EGF along the gastrointestinal
tract mucosa.
To verify the nature of the observed immunoreactivity,
reverse phase chromatography was carried out on samples of
gastric mucosal extracts (Figure 2). hTGFa and hURO-EGF
immunoreactivity were found to coelute exactly with hTGFa
and hURO-EGF standards previously applied to the column.
hTGFo eluted at 25% acetonitrile (peak retention 36 ml) and
hURO-EGF at 30% acetonitrile (peak retention 42 ml).
Gastrointestinal mucosal extracts from a 7-year-old female
contained higher levels of hTGFa than corresponding adult
tissue extracts, with the exception of that derived from the
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Figure 1 Human transforming growth factor ax (0) and human
urogastrone (U) epidermal growth factor mean values (ng per g
tissue wet weight) in the mucosa from normal human adult
stomach, duodenum, jejunum, ileum, ascending colon, transverse
colon, descending colon and sigmoid colon. Measured by specific
radioimmunoassays.
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Figure 2 Profile of extract of normal human gastric mucosa
obtained by reversed phase chromotography on FPLC using an
acetonitrile gradient (e) showing separation of peptide peaks
and coinciding positions of elution ofpure hTGF (O) and URO-
ERG (0) with the peaks obtained in the biological extract.
stomach (Figure 3), and the distribution of hTGFa was also
markedly different. The level of hTGFa was also markedly
different. The level of hTGFa in the gastric mucosa (2,200 pg
per gram wet weight of tissue) was similar to the average
adult level, but this level was maintained throughout the
duodenum and jejunem, rising to 5,042 pg g-' in the ileum.
hTGFa levels did not decline in the large bowel with
5,119 pg g-' present in the sigmoid colon. hURO-EGF was
not detected in the mucosal extracts from this individual.
Extracts of submucosal tissues from the same regions of
the gastrointestinal tract of the 7-year-old were also
examined, but neither hURO-EGF nor hTGFa were detected
in these samples. The apparent absence of hURO-EGF in
these submucosal samples was supported by routine
immunocytochemical analysis (results not shown), which also
failed to detect hURO-EGF in duodenal Brunner's glands atEGF AND TGF aIN NORMAL HUMAN GUT MUCOSA 659
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Figure 3 Levels of hTGFa seen in different regions of gast-
rointestinal mucosa from a 7-year-old female. hURO-EGF levels
were undetectable.
this age. The avidin-biotin method employed the same
antibody used for hURO-EGF radioimmunoassay, and adult
control tissue showed positive staining for EGF in Brunner's
glands of the duodenum (data on file).
Discussion
The presence of hURO-EGF in human submandibular
glands, saliva, stomach, gastric juice and Brunner's glands,
together with the finding that the hURO-EGF receptor is
expressed throughout the gastrointestinal mucosa, has led to
the proposal that this peptide plays a role in normal gastro-
intestinal epiithelial maintenance. Recent studies in the rabbit
suggest that hURO-EGF may play an important role in
post-natal hepatic growth and maturation (Opleta et al.,
1987). The present study demonstrated that hTGFa, which
also binds to and activates the hURO-EGF receptor kinase,
is present throughout the normal gastrointestinal mucosa in
significantly higher quantities than hURO-EGF. This finding
suggests that this peptide, which until recently was thought
to be tumour and embryo specific may be also involved in
the control of normal cell renewal in the epithelial lining of
the gut.
The possibility that these peptides are not produced by the
gastrointestinal mucosa but are sequestered by them cannot
be discounted. Indeed, the low levels of hURO-EGF detected
in most of the adult tissues may represent the peptide con-
tained within platelets present in the mucosal samples prior
to extraction. Previous work in our laboratory has shown
that up to 11 ng of hURO-EGF per ml of serum can be
released from platelets following the storage of whole blood
from normal individuals. We have not, however, detected
hTGFa in the platelets or serum of normal individuals
(n = 6) or of patients suffering from gastrointestinal cancer
(n = 12) (unpublished observations).
The presence of hTGFa in the stomach and duodenum,
implies the simultaneous production of two distinct molecules
with affinities for the same receptor. EGF in. intracellular
granules positive by the immunoperoxidase technique have
been described (Elder et al., 1986), but TGFa specific
localisation is not kown. The reasons for the presence of
these highly similar peptides in the same tissue remain obs-
cure. However, Derynck (1986) suggest that there are subtle
differences in cellular responses to the binding of EGF and
TGFa in specific in vitro and in vivo experimental models.
For example, TGFa is reported to elicit a greater effect in
inducing the formation of epidermal cell colonies in soft agar
than does EGF; TGFo appears more effective than EGF in
the induction of cell ruffling (Myrdal, 1985) and is more
potent in stimulating osteoclast precursor cells (Ibbotson et
al., 1986). TGFa has also been shown to induce neovas-
cularisation in hamster cheek pouches at much lower concen-
trations than EGF (Schreiber et al., 1986), and was much
more effective than EGF in terms of producing a maximum
increase in blood flow in an experimental model (Gan et al.,
1987). Moreover TGFa appears to have the ability to
regulate vascular reactivity without desensitisation as is seen
with EGF and Gan et al. have pointed that this may have a
potential role in the progression of tumours secreting TGFa.
Coffey et al. (1987) have recently reported that the addi-
tion of EGF or TGFa to primary cultures of neonatal
human keratinocycles induces TGFa gene expression. They
propose that this possible autoregulation of cell proliferation
could be responsible for amplification of the growth factor
response. If this is indeed the case, the release of EGF in gut
epithelium, following a specific stimulus, could result in the
autocrine secretion of TGFa and the possibility of subse-
quent cell proliferation.
The profile of hTGFa levels along the adult gastrointes-
tinal tract mucosa shows lower levels in the duodenum and
jejunum. Since hURO-EGF has been localised to the sub-
mucosal Brunner's glands, a reciprocal inverse relationship
may exist between the two peptides in these areas of rapid
cell renewal. Distally, hTGFa levels rise first and then decline
again along the colon. It is interesting to note that lower
levels of hTGFa and very little hURO-EGF are present in
the descending and sigmoid colon, the most common sites of
gastrointestinal tumour formation. In contrast, hTGFa levels
detected in the extracts of colonic mucosa derived from the
juvenile did not decline and in the sigmoid colon were
approximately 10 times higher than in the corresponding
adult tissue extracts. Colonic cancers are virtually unknown
in children. However, only one juvenile has been studied and
the distribution described requires confirmation by further
reports.
Little is known in the human species about the regulation
of hURO-EGF or hTGFa synthesis. Studies in the mouse
suggest that EGF concentration in the submandibular gland
is influenced by androgens, thyroid hormones, progesterone
and oestrogen, probably by means of alteration of the syn-
thesis of prepro-EGF (Gresik et al., 1981; Walker et al.,
1981; Bullock et al., 1975; Kurachi & Oka, 1986; Grubits et
al., 1986). Further studies are now required to determine if
the gut is a target organ for these well established regulatory
hormones as regards EGF and TGFa synthesis. The area of
origins, actions, physiological roles and relationship between
production of EGF or TGFa to cancer induction and metas-
tasis has recently been reviewed (Burgess, 1989), but evidence
is mounting that these peptides may be of much more
physiological than pathological importance.
We should like to thank Mrs Louise Ellis of the North Staffordshire
Medical Institute for typing the manuscript and the Department of
Medical Illustration, North Staffordshire Royal Infirmary for the
charts and photographs.
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